FIELD: biotechnology.
SUBSTANCE: method of treating an acute episode of acquired thrombotic thrombocytopenic purpura (TTP) in a person in need of it is described. The method includes the stages of performing a previous plasma exchange (PEX), administering a first dose of a polypeptide in the amount of 1–80 mg to the specified person, performing a PT, administering a subsequent dose of the specified polypeptide in the amount of 1–80 mg, where the specified polypeptide contains the following SEQ ID NO: 1.
EFFECT: invention expands the arsenal of methods of treating an acute episode of acquired thrombotic thrombocytopenic purpura (TTP).
3 cl, 6 dwg, 12 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR TREATMENT OF INITIAL EPISODE OF TTP USING SINGLE VARIABLE DOMAINS OF IMMUNOGLOBULINS | 2019 |
|
RU2794143C2 |
| ADVANCED SERUM ALBUMIN BINDING AGENTS | 2018 |
|
RU2797270C2 |
| POLYPEPTIDES BINDING TO ADAMTS5, MMP13, AND AGGRECAN | 2018 |
|
RU2786659C2 |
| MMP13-BINDING IMMUNOGLOBULINS | 2018 |
|
RU2784069C2 |
| IMPROVED SUBSTANCES BINDING TO SERUM ALBUMIN | 2018 |
|
RU2789495C2 |
| ADAMTS-BINDING IMMUNOGLOBULINS | 2018 |
|
RU2781182C2 |
| IMPROVED SINGLE VARIABLE IMMUNOGLOBULIN DOMAINS BINDING TO SERUM ALBUMIN | 2017 |
|
RU2765384C2 |
| POLYPEPTIDES MODULATING SIGLEC-DEPENDENT IMMUNE RESPONSES | 2017 |
|
RU2776807C2 |
| IMPROVED TNF-BINDING AGENTS | 2016 |
|
RU2774823C2 |
| PD1/CTLA4-BINDING SUBSTANCES | 2016 |
|
RU2755724C2 |
